Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.41 |
| ▸ | NPY4R | P50391 | 4/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823292 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL21230049 | 0.98 | SIRT2 (0.43) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL25830938 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL24068203 | 0.94 | SIRT2 (0.46) | SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL24068330 | 0.94 | SIRT2 (0.46) | SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL18914850 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL23330252 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL23106472 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL26319897 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL18823533 | 0.92 | CHRNA1 (0.38) | SIRT2SIRT1SIRT3SIRT5FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | Mersana Therpeutics, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10316080-B2 | Protein-polymer-drug conjugates | ASANA BIOSCIENCES, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SIRT2 2841/4885SIRT1 2541/4885NPY4R 4497/4885 |
| US-10316080-B2 | Protein-polymer-drug conjugates | PBRM1, STAMBP, TSPO | SIRT2 2841/4885SIRT1 2541/4885NPY4R 4497/4885 |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | SIRT2 3975/4885SIRT1 4075/4885NPY4R 1660/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SIRT2 2534/4885SIRT1 2369/4885NPY4R 4305/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SIRT2 2841/4885SIRT1 2541/4885NPY4R 4497/4885 |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | PBRM1, BRAP, STAMBP | SIRT2 3114/4885SIRT1 2931/4885NPY4R 4329/4885 |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | SIRT2 3566/4885SIRT1 3985/4885NPY4R 2938/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | SIRT2 3975/4885SIRT1 4075/4885NPY4R 1660/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SIRT2 2205/4885SIRT1 1989/4885NPY4R 3996/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | SIRT2 2262/4885SIRT1 2098/4885NPY4R 3980/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | SIRT2 3975/4885SIRT1 4075/4885NPY4R 1660/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | SIRT2 1983/4885SIRT1 1678/4885NPY4R 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.